ARS Pharmaceuticals

Yahoo Finance • 14 days ago

Ars Pharmaceuticals anticipates CVS Caremark decision as it expands $199 retail access program

Earnings Call Insights: ARS Pharmaceuticals (SPRY) Q1 2026 MANAGEMENT VIEW * “We are off to a strong start in 2026... building momentum across the business,” said (Co-Founder, President, CEO & Director Richard Lowenthal), highlighting... Full story

Yahoo Finance • 14 days ago

ARS Pharma (SPRY) Q4 2025 Earnings Transcript

Image source: The Motley Fool. DATE Monday, March 9, 2026, at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Richard LowenthalChief Commercial Officer — Eric KarasChief Financial Officer — Kathleen Scott Need a quote from a... Full story

Yahoo Finance • 14 days ago

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.1% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 15 days ago

ARS Pharmaceuticals Q1 Earnings Call Highlights

Key Points Interested in ARS Pharmaceuticals, Inc.? Here are five stocks we like better. ARS Pharmaceuticals reported $22.7 million in first-quarter 2026 revenue, with U.S. net product revenue for neffy reaching $17.5 million as prescript... Full story

Yahoo Finance • 15 days ago

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Q1 2026 total revenue of $22.7 million including neffy® (epinephrine nasal spray)U.S. net product revenue of $17.5 million CVS Caremark proposal in final stages of approval process; definitive update anticipated in early June Sales for... Full story

Yahoo Finance • 15 days ago

Here are the major earnings before the open Friday

Major earnings expected before the bell on Friday include: * Sachem Capital Corp. (SACH [https://seekingalpha.com/symbol/SACH]) * Mizuho Financial Group (MFG [https://seekingalpha.com/symbol/MFG]) * Datavault AI (DVLT [https://seeki... Full story

Yahoo Finance • 23 days ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could... Full story

Yahoo Finance • last month

Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver

We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. ARS Pharmaceuticals, Inc. is another best biotech stock under $10 to buy. TheFly reported on April 9 that Northland initiated coverage of SPRY with an Outperform... Full story

Yahoo Finance • last month

neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

neffy offers a new delivery method for epinephrine in Canada for adults and children (>30 kg) living with severe allergic reactions ALK- Abelló A/S, which licenses the rights to market neffy in Canada, expects availability in the summer o... Full story

Yahoo Finance • 3 months ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * 3D Systems Corporation (DDD [https://seekingalpha.com/symbol/DDD]) * FuelCell Energy (FCEL [https://seekingalpha.com/symbol/FCEL]) * Zim Integrated Shipping Services Ltd.... Full story

Yahoo Finance • 3 months ago

Dan Loeb's Third Point takes new stake in Chipotle Mexican Grill, Alibaba in Q4 moves

Dan Loeb's Third Point took new stakes in Chipotle Mexican Grill (CMG [https://seekingalpha.com/symbol/CMG]), Alibaba (BABA [https://seekingalpha.com/symbol/BABA]), and Spotify (SPOT [https://seekingalpha.com/symbol/SPOT]), while increasin... Full story

Yahoo Finance • 3 months ago

Got $300? 2 Biotech Stocks to Buy and Hold Forever

Krystal Biotech(NASDAQ: KRYS) and ARS Pharmaceuticals(NASDAQ: SPRY) have been gaining a lot of attention over the past year, thanks to the potential in their groundbreaking -- and for now, only -- commercial therapies. In 2023, Krystal pi... Full story

Yahoo Finance • 5 months ago

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

ARS Pharmaceuticals, Inc. neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (>30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a license from... Full story

Yahoo Finance • 6 months ago

ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that co... Full story

Yahoo Finance • 7 months ago

ARS Pharmaceuticals targets renewed growth in 2026 as neffy adoption accelerates and new global launches begin

Earnings Call Insights: ARS Pharmaceuticals (SPRY) Q3 2025 MANAGEMENT VIEW * Richard Lowenthal, Co-Founder, President, CEO & Director, highlighted a pivotal quarter for ARS Pharma, stating "U.S. net product revenue for neffy grew again... Full story

Yahoo Finance • 7 months ago

ARS Pharmaceuticals GAAP EPS of -$0.52 misses by $0.05, revenue of $32.5M beats by $3.82M

* ARS Pharmaceuticals press release [https://seekingalpha.com/pr/20299947-ars-pharmaceuticals-reports-third-quarter-2025-financial-results-and-highlights-for-neffy] (SPRY [https://seekingalpha.com/symbol/SPRY]): Q3 GAAP EPS of -$0.52 mis... Full story

Yahoo Finance • 7 months ago

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world evidence, expected to accelerate with... Full story

Yahoo Finance • 7 months ago

ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy® (epinephrine nasal spray) Oral presentation reports about 9 out of every 10 patients experiencing anaphylaxis w... Full story

Yahoo Finance • 8 months ago

ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

Initial $100 million term loan to propel market share growth in the U.S. SAN DIEGO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-ris... Full story

Yahoo Finance • 8 months ago

Sector Update: Health Care Stocks Mixed Late Afternoon

Health care stocks were mixed late Friday afternoon, with the NYSE Health Care Index easing 0.1% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story